8 results on '"Cornelius Dyke"'
Search Results
2. Predicting Outcomes in NSCLC: Staging or Biology or Both?
- Author
-
Cecilia L. Benz and Cornelius Dyke
- Subjects
Surgery ,RD1-811 - Published
- 2021
- Full Text
- View/download PDF
3. A multicenter, prospective, controlled clinical trial of surgical stabilization of rib fractures in patients with severe, nonflail fracture patterns (Chest Wall Injury Society NONFLAIL)
- Author
-
Babak Sarani, Kiara Leasia, Frank Zhao, Zach Bauman, Cornelius Dyke, Sarah Majercik, Gregory Semon, Lawrence Lottenberg, Evert A. Eriksson, Fredric M. Pieracci, Bradley W Thomas, Ledford Powell, and Andrew R. Doben
- Subjects
Adult ,Male ,Flail chest ,medicine.medical_specialty ,Adolescent ,Rib Fractures ,Fractures, Multiple ,Critical Care and Intensive Care Medicine ,Pulmonary function testing ,law.invention ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Fracture Fixation ,law ,Fracture fixation ,Humans ,Medicine ,Prospective Studies ,Prospective cohort study ,Aged ,Pain Measurement ,Hemothorax ,Pain, Postoperative ,Trauma Severity Indices ,business.industry ,030208 emergency & critical care medicine ,Middle Aged ,medicine.disease ,Thoracostomy ,Empyema ,Surgery ,Treatment Outcome ,Female ,business - Abstract
BACKGROUND The efficacy of surgical stabilization of rib fracture (SSRF) in patients without flail chest has not been studied specifically. We hypothesized that SSRF improves outcomes among patients with displaced rib fractures in the absence of flail chest. METHODS Multicenter, prospective, controlled, clinical trial (12 centers) comparing SSRF within 72 hours to medical management. Inclusion criteria were three or more ipsilateral, severely displaced rib fractures without flail chest. The trial involved both randomized and observational arms at patient discretion. The primary outcome was the numeric pain score (NPS) at 2-week follow-up. Narcotic consumption, spirometry, pulmonary function tests, pleural space complications (tube thoracostomy or surgery for retained hemothorax or empyema >24 hours from admission) and both overall and respiratory disability-related quality of life (RD-QoL) were also compared. RESULTS One hundred ten subjects were enrolled. There were no significant differences between subjects who selected randomization (n = 23) versus observation (n = 87); these groups were combined for all analyses. Of the 110 subjects, 51 (46.4%) underwent SSRF. There were no significant baseline differences between the operative and nonoperative groups. At 2-week follow-up, the NPS was significantly lower in the operative, as compared with the nonoperative group (2.9 vs. 4.5, p < 0.01), and RD-QoL was significantly improved (disability score, 21 vs. 25, p = 0.03). Narcotic consumption also trended toward being lower in the operative, as compared with the nonoperative group (0.5 vs. 1.2 narcotic equivalents, p = 0.05). During the index admission, pleural space complications were significantly lower in the operative, as compared with the nonoperative group (0% vs. 10.2%, p = 0.02). CONCLUSION In this clinical trial, SSRF performed within 72 hours improved the primary outcome of NPS at 2-week follow-up among patients with three or more displaced fractures in the absence of flail chest. These data support the role of SSRF in patients without flail chest. LEVEL OF EVIDENCE Therapeutic, level II.
- Published
- 2019
- Full Text
- View/download PDF
4. Pulmonary Artery-Tracheal Fistula After Coil Implantation for Behcet’s Disease
- Author
-
Dwayne M. Hansen and Cornelius Dyke
- Subjects
medicine.medical_specialty ,Pulmonology ,Behcet's disease ,Disease ,030204 cardiovascular system & hematology ,coil embolization ,03 medical and health sciences ,High morbidity ,0302 clinical medicine ,Rheumatology ,medicine.artery ,medicine ,behcet’s syndrome ,Tracheal fistula ,Coil embolization ,business.industry ,coil migration ,General Engineering ,medicine.disease ,Surgery ,tracheal foreign body ,Cardiac/Thoracic/Vascular Surgery ,Pulmonary artery ,pulmonary artery aneurysm ,Vasculitis ,business ,Complication ,030217 neurology & neurosurgery ,pulmonary artery - tracheal fistula - Abstract
Behcet’s disease (BD) is a rare autoimmune disorder that results in diffuse full-thickness vasculitis. Pulmonary artery aneurysms (PAAs) and hemoptysis are known complications of this disease process, with high morbidity and mortality for affected patients. Although medical, endovascular, and surgical treatment strategies have all been described in the literature, there are little data to describe the long-term outcomes of these various treatment modalities and there continues to be a lack of clearly defined algorithms for the management of these patients. We report a case of PAA in the setting of BD who was treated over the course of many years with medical therapy and coil embolization but ultimately failed treatment, sustained a complication of coil erosion and migration into the trachea twice, and required surgical lobectomy for definitive management. We discuss an algorithm for the management of patients with BD who have PAAs.
- Published
- 2020
- Full Text
- View/download PDF
5. Authors' Response to letter by Elkbuli et al
- Author
-
Lawrence Lottenberg, Babak Sarani, Gregory Semon, Evert A. Eriksson, Kiara Leasia, Cornelius Dyke, Ledford Powell, Frank Zhao, Sarah Majercik, Zach Bauman, Andrew R. Doben, Fredric M. Pieracci, and Bradley W Thomas
- Subjects
Rib Fractures ,Thoracic Injuries ,business.industry ,Critical Care and Intensive Care Medicine ,computer.software_genre ,Text mining ,Humans ,Medicine ,Surgery ,Prospective Studies ,Artificial intelligence ,Thoracic Wall ,business ,computer ,Natural language processing - Published
- 2020
- Full Text
- View/download PDF
6. TCT-95 A Novel Approach to Percutaneous Removal of Right-Sided Valvular Vegetations Using Suction Filtration and Veno-Venous Bypass Circuit
- Author
-
Puneet Sharma, Cornelius Dyke, Mahammed Khan Suheb, and Thomas Haldis
- Subjects
Suction (medicine) ,medicine.medical_specialty ,Percutaneous ,business.industry ,Percutaneous techniques ,medicine.disease ,Veno venous bypass ,law.invention ,Surgery ,Refractory ,law ,Infective endocarditis ,cardiovascular system ,medicine ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,Filtration - Abstract
Traditional management of right-sided infective endocarditis (RSIE) involved intravenous (IV) antibiotics and valvular surgery for refractory cases. Recent advances in percutaneous techniques allow removal of large valvular vegetations using the AngioVac (AngioDynamics, New York) system, which
- Published
- 2019
- Full Text
- View/download PDF
7. Cabled butterfly closure: a novel technique for sternal closure
- Author
-
Cornelius Dyke, Shashank Jolly, and Beau Flom
- Subjects
Pulmonary and Respiratory Medicine ,Novel technique ,Adult ,Male ,medicine.medical_specialty ,Sternum ,Heart Diseases ,medicine.medical_treatment ,Closure (topology) ,Young Adult ,Surgical Wound Dehiscence ,medicine ,Humans ,Cardiac Surgical Procedures ,Aged ,Retrospective Studies ,Aged, 80 and over ,Wound Healing ,Sutures ,business.industry ,Suture Techniques ,Equipment Design ,Surgical procedures ,Middle Aged ,musculoskeletal system ,Sternotomy ,Surgery ,body regions ,surgical procedures, operative ,Treatment Outcome ,Median sternotomy ,Sternal dehiscence ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Impaired sternal wound healing remains problematic after median sternotomy and can lead to significant morbidity after cardiac surgical procedures. Although metal plating systems exist for closing the sternum, their use is limited by expense and practicality, and simple wire closure remains the most common technique to close the sternum. We describe a cabling technique for sternal closure that is secure, uses standard sternal wire, and may be used on every patient. We have used the technique routinely in 291 patients with no sternal dehiscence or wound healing problems.
- Published
- 2012
8. Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery
- Author
-
Dominick J. Angiolillo, Michael S. Firstenberg, Matthew J. Price, Pradyumna E. Tummala, Martin Hutyra, Ian J. Welsby, Michele D. Voeltz, Harish Chandna, Chandrashekhar Ramaiah, Miroslav Brtko, Louis Cannon, Cornelius Dyke, Tiepu Liu, Gilles Montalescot, Steven V. Manoukian, Jayne Prats, Eric J. Topol, and for the BRIDGE Investigators
- Subjects
Adult ,Male ,medicine.medical_specialty ,Thienopyridines ,Thienopyridine ,medicine.medical_treatment ,Blood Loss, Surgical ,Coronary Artery Disease ,Postoperative Hemorrhage ,Placebo ,Article ,chemistry.chemical_compound ,Coronary artery bypass surgery ,Cangrelor ,Double-Blind Method ,Multicenter trial ,Coronary stent ,medicine ,Humans ,Platelet activation ,Acute Coronary Syndrome ,Coronary Artery Bypass ,Aged ,Aged, 80 and over ,business.industry ,Thrombosis ,General Medicine ,Middle Aged ,Platelet Activation ,Adenosine Monophosphate ,Surgery ,chemistry ,Anesthesia ,Purinergic P2Y Receptor Antagonists ,Platelet aggregation inhibitor ,Female ,Stents ,business ,Platelet Aggregation Inhibitors - Abstract
Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding.To evaluate the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery.Prospective, randomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting CABG surgery to receive either cangrelor or placebo after an initial open-label, dose-finding phase (n = 11) conducted between January 2009 and April 2011. Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was discontinued 1 to 6 hours before CABG surgery.The primary efficacy end point was platelet reactivity (measured in P2Y(12) reaction units [PRUs]), assessed daily. The main safety end point was excessive CABG surgery-related bleeding.The dose of cangrelor determined in 10 patients in the open-label stage was 0.75 μg/kg per minute. In the randomized phase, a greater proportion of patients treated with cangrelor had low levels of platelet reactivity throughout the entire treatment period compared with placebo (primary end point, PRU240; 98.8% (83 of 84) vs 19.0% (16 of 84); relative risk [RR], 5.2 [95% CI, 3.3-8.1] P.001). Excessive CABG surgery-related bleeding occurred in 11.8% (12 of 102) vs 10.4% (10 of 96) in the cangrelor and placebo groups, respectively (RR, 1.1 [95% CI, 0.5-2.5] P = .763). There were no significant differences in major bleeding prior to CABG surgery, although minor bleeding episodes were numerically higher with cangrelor.Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.clinicaltrials.gov Identifier: NCT00767507.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.